Insys Therapeutics, Inc. (INSY) [Rocket]

In millions, except per share items	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	S-1/A
Net revenue	82.1	140.7	242.3	330.3	219.1	99.3	15.5
Net revenue growth	-41.7%	-41.9%	-26.7%	50.8%	120.7%	541.6%
Cost of revenue	10.8	20.6	25.4	28.9	22.6	12.7	7.6
Gross profit	71.3	120.1	216.9	301.5	196.5	86.6	7.8
Gross margin	86.8%	85.3%	89.5%	91.3%	89.7%	87.2%	50.7%

Operating expenses:
Sales and marketing	31.4	48.9	69.7	80.7	58.1	29.2	11.4
Research and development	57.6	63.0	73.9	56.8	33.1	8.5	6.3	8.3
General and administrative	39.3	46.5	42.1	62.9	44.3	16.4	8.2	9.0
Legal	54.0	21.1	20.0
Charges related to litigation award and settlements	54.0	21.1	20.0
Total operating expenses	199.0	339.1	209.6	430.9	288.0	109.8	31.3	17.4
Operating loss	-127.7	-219.0	7.3	90.5	61.0	32.6	-23.4	-17.4
Operating margin	-155.6%	-155.7%	3.0%	27.4%	27.8%	32.8%	-151.5%

Other income (expense):
Interest income	2.0	1.9	1.0	0.5	0.2	0.0
Other expense, net	-0.7	0.0	0.1	0.0	0.0	-0.1	1.7
Total other income (expense)	1.3	1.8	1.1	0.5	0.2	-1.0	0.8
Loss before income taxes	-126.4	-217.2	8.4	91.0	61.1
Income tax expense	-1.9	9.6	0.8	32.9	25.1	-8.8
Net loss	-124.5	-226.8	7.6	58.1	36.1	40.4	-24.4
Total comprehensive loss	-124.3	-227.0	7.4	57.9	36.0	40.4

Net loss per common share:
Basic	($1.68)	($3.12)	$0.11	$0.81	$0.52	$0.78	($2.62)	($2.08)
Diluted	($1.68)	($3.12)	$0.10	$0.77	$0.49	$0.70	($2.62)	($2.08)

Weighted average common shares outstanding
Basic	74.1	72.6	71.6	71.6	68.8	51.8	9.3	0.8
Diluted	74.1	72.6	74.2	75.7	73.3	57.5	9.3	0.8